AU2001282560A1 - Methods of infection with hepatitis c virus - Google Patents

Methods of infection with hepatitis c virus

Info

Publication number
AU2001282560A1
AU2001282560A1 AU2001282560A AU8256001A AU2001282560A1 AU 2001282560 A1 AU2001282560 A1 AU 2001282560A1 AU 2001282560 A AU2001282560 A AU 2001282560A AU 8256001 A AU8256001 A AU 8256001A AU 2001282560 A1 AU2001282560 A1 AU 2001282560A1
Authority
AU
Australia
Prior art keywords
hepatitis
virus
infection
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282560A
Inventor
Asao Katsume
Michinori Kohara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Tokyo Metropolitan Organization for Medical Research
Original Assignee
TOKYO METROPOLITAN ORG MED RES
Chugai Pharmaceutical Co Ltd
Tokyo Metropolitan Organization for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOKYO METROPOLITAN ORG MED RES, Chugai Pharmaceutical Co Ltd, Tokyo Metropolitan Organization for Medical Research filed Critical TOKYO METROPOLITAN ORG MED RES
Publication of AU2001282560A1 publication Critical patent/AU2001282560A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
AU2001282560A 2000-10-03 2001-08-30 Methods of infection with hepatitis c virus Abandoned AU2001282560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000303374 2000-10-03
JP2000-303374 2000-10-03
PCT/JP2001/007498 WO2002028174A1 (en) 2000-10-03 2001-08-30 Methods of infection with hepatitis c virus

Publications (1)

Publication Number Publication Date
AU2001282560A1 true AU2001282560A1 (en) 2002-04-15

Family

ID=18784582

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282560A Abandoned AU2001282560A1 (en) 2000-10-03 2001-08-30 Methods of infection with hepatitis c virus

Country Status (5)

Country Link
US (1) US20040101827A1 (en)
EP (1) EP1327687A4 (en)
JP (1) JPWO2002028174A1 (en)
AU (1) AU2001282560A1 (en)
WO (1) WO2002028174A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2769879C (en) 2009-08-28 2015-06-09 Tokyo Metropolitan Institute Of Medical Science Polynucleotide derived from novel hepatitis c virus strain and use thereof
CN109453155A (en) * 2018-09-30 2019-03-12 广州医科大学附属第医院 For assessing the construction method of the tree shrew model of anti-influenza virus medicament pharmacokinetics and pharmacodynamics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858328A (en) * 1991-06-04 1999-01-12 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
ATE377944T1 (en) * 1995-09-27 2007-11-15 Gen Hospital Corp METHOD FOR TREATING HEPATITIS VIRUS INFECTION
US5851758A (en) * 1995-10-25 1998-12-22 Childrens Research Institute Cytopathic replication of hepatitis C virus in a new cell line
AU761012B2 (en) * 1998-06-24 2003-05-29 Chugai Seiyaku Kabushiki Kaisha Vector expressing the full-length gene of RNA virus and use thereof
JP2000152793A (en) * 1998-06-24 2000-06-06 Tokyoto Igaku Kenkyu Kiko Vector for expressing complete length gene of rna virus and its use
US6509514B1 (en) * 2000-03-17 2003-01-21 Kmt Hepatech, Inc. Chimeric animal model susceptible to human hepatitis C virus infection

Also Published As

Publication number Publication date
WO2002028174A1 (en) 2002-04-11
US20040101827A1 (en) 2004-05-27
EP1327687A1 (en) 2003-07-16
JPWO2002028174A1 (en) 2004-02-12
EP1327687A4 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2002210450A1 (en) Maintaining virus detection software
AU2002230763A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001282528A1 (en) Compounds having anti-hepatitis c virus effect
AU2158000A (en) Treatment of hepatitis c virus infections with interleukin-10
AU2003216523A1 (en) Treatment of pre-core hepatitis b virus mutant infections
AU3714499A (en) Hepatitis c virus mimotopes
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
PL373675A1 (en) Hepatitis b virus treatment
AU2001296864A1 (en) Detection of varicella-zoster virus
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
AU2003294757A1 (en) Formulations useful against hepatitis c virus infections
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
AU2001292667A1 (en) Immunogenic composition of hepatitis c and methods of use thereof
AU2281601A (en) Treatment of viral infections using levovirinTM
AU2001292947A1 (en) Methods for inhibition of viral infection
AU2001282560A1 (en) Methods of infection with hepatitis c virus
AU2003301865A1 (en) Epitopes of hepatitis c virus
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
AU2001257505A1 (en) Hepatitis c virus helicase crystals, crystallographic structure and methods
AU2003289016A1 (en) Method of distinguishing drug-resistance of hepatitis b virus
AU2001254670A1 (en) Detection of hepatitis b virus rna
AU2003287216A1 (en) Gb virus c and methods of treating viral infections